

IN THE SPECIFICATION

Please amend the paragraph beginning at page 6, line 5 as follows:

C! --The invention is based on the discovery that an homogenate prepared from cells of *Neospora* is capable of inducing a protective response against neosporosis in mammals. The cells used to produce the homogenate in the vaccine of the present invention may be derived from any strain of any species of the genus *Neospora*, which cells may or may not be pathogenic, where the homogenate is capable of inducing a protective response against neosporosis in mammals. In a preferred embodiment, the species of *Neospora* is *N. caninum*. A non-limiting example of a strain of *N. caninum* from which an homogenate may usefully be prepared is strain NC-1, which is available in infected MARC145 monkey kidney cells, deposited on November 6, 1996 with ~~from~~ the American Type Culture Collection, located at ~~12301 Parklawn Drive, Rockville, MD 20852~~ 10801 University Boulevard, Manassas, VA 2-110-2209, USA (ATCC Accession No. CRL-12231), and which encompasses strains derived from NC-1 by one or more *in vitro* and/or *in vivo* passages. Strain NC-1 is also described in Dubey et al., 1988, J. Am. Vet. Med. Assoc. 193: 1259-1263, which publication is incorporated herein by reference. Strains of *Neospora* for use according to the present invention may alternatively be isolated from organs, tissues or body fluids of infected animals using standard isolation techniques, such as those described in the publications reviewed above.--